Drug Trial Radar · NCT02149173
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
Last checked: Nov 20, 2026Latest source record: Jun 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
29
Actual
Start
Sep 15, 2010
Primary completion
Dec 27, 2018
Study completion Jan 13, 2021
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 29, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.
Conditions
- Estrogen Receptor Positive
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7
Interventions
Computed TomographyProcedure
Undergo F-18 FES PET/CT
Computed TomographyProcedure
Undergo FDG PET/CT
F-18 16 Alpha-FluoroestradiolDrug
Undergo F-18 FES PET/CT
Fludeoxyglucose F-18Drug
Undergo FDG PET/CT
Laboratory Biomarker AnalysisOther
Correlative studies
Positron Emission TomographyProcedure
Undergo F-18 FES PET/CT
Positron Emission TomographyProcedure
Undergo FDG PET/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV), Assessed by a One-sample Test of the Percent Change in FES SUVTime frame: from time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 2-8 weeks)
- F-18 16 Alpha-fluoroestradiol (FES) UptakeTime frame: from time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 2-8 weeks)
- Proportion of Patients Experienced a Threshold in Percentage Change, or Surpassed a Targeted Follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV)Time frame: from time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 2-8 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.